Cas:679796-43-1 (S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL manufacturer & supplier

Chemical Name:(S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL

CAS.NO:679796-43-1

Synonyms:(S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL

Molecular Formula:C₁₆H₁₈ClNO₂

Molecular Weight:291.77300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:456.8ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:49.33000

Exact Mass:291.10300

LogP:3.71990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL Use and application,(S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL technical grade,usp/ep/jp grade.

Related News: Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� (S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL manufacturer Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). (S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL supplier The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry. (S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL vendor We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� (S)-α-(2-NAPHTHALENYLMETHYL)-PROLINE-HCL factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��